Herpangina: Clinical Trials

2 completed. 2 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Completed 2
Phase 2	2	Completed 2

Follow Herpangina: new trials by email Literature Review of Herpangina trials Research Report on Herpangina

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell), Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell), High-dose tetravalent inactivated enterovirus vaccine (Vero cell) ) - Hand, Foot, and Mouth Disease (HFMD), Herpangina	Phase 1 / Phase 2	Completed	Sinovac Biotech Co., Ltd	552	2025-01-15	2026-03-04
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated - Hand, Foot and Mouth Disease, Herpangina	Phase 1 / Phase 2	Completed	Sinovac Biotech Co., Ltd	744	2023-09-20	2026-06-26

Narrower conditions

Hand, Foot and Mouth Disease (2)

Broader conditions

Coxsackievirus Infections (2)  ·  Echovirus Infections (2)  ·  Enterovirus Infections (2)  ·  Infections (2)  ·  Picornaviridae Infections (2)  ·  RNA Virus Infections (2)  ·  Virus Diseases (2)

Sponsors

Sinovac Biotech Co., Ltd (2)

Countries

China (2)

Top investigators

Wang Shenyu, Dr. (1)  ·  Zheng Yan (1)